CHRS

Coherus Oncology, Inc., operating as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused on developing and commercializing biosimilars and innovative oncology therapies. The company's portfolio includes biosimilar versions of widely used cancer treatments, offering more affordable alternatives to expensive reference biologics. Coherus leverages its expertise in protein engineering and manufacturing to bring high-quality biosimilars to market. The company also develops novel immuno-oncology therapies targeting various cancer types. CHRS's business model depends on regulatory approvals, market adoption of biosimilars, and successful clinical trial outcomes for pipeline candidates. The company faces competition from both originator biologic manufacturers and other biosimilar developers. Coherus Oncology's revenue growth is driven by expanding market share in existing products and advancing its pipeline through clinical development and regulatory milestones.